Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.

Verified November 2005 by Biosyn.
Recruitment status was: Not yet recruiting

Sponsor:

Collaborator:

National Institute of Allergy and Infectious Diseases (NIAID)

Information provided by:

Biosyn

ClinicalTrials.gov Identifier:

NCT00260767

First received: November 30, 2005

Last updated: NA

Last verified: November 2005

History: No changes posted

Purpose

Condition	Intervention	Phase
HIV	Drug: HEC placebo gel	Phase 1


Study Type:	Interventional
Study Design:	Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	An Imaging Trial of the Distribution of Topical Gel in the Human Vagina: Enhanced MRI Techniques to Increase Resolution

Further study details as provided by Biosyn:

Primary Outcome Measures:

1. Number and size of bare spots, before and after simulated coitus.
2. Number of women with migration of gel into the endocervical canal and/or endometrial canal before and after simulated coitus.


Estimated Enrollment:	6

Detailed Description:

This study will assess the distribution of topical gel in the human vagina, using enhanced MRI techniques. The number and size of uncovered areas will be studied, and the upper genital tract will be examined for the presence of topical gel using MRI. MRIs will be performed with both a standard pelvic coil and an enhanced resolution endo-rectal coil in order to obtain maximal resolution. MRI images will be acquired before and after simulated coitus.

Eligibility


Ages Eligible for Study:	18 Years to 45 Years (Adult)
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

18 to 45 year old women
not pregnant
willingness to use effective method of contraception
regular menstrual cycle
normal Pap test result

Exclusion Criteria:

abnormal pelvic exam
pregnant or breastfeeding
claustrophobia or other MRI contraindications
hypertension, hemolytic anemia,latex allergy
history of hemorrhoids or irritable bowel syndrome

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00260767

Contacts


Contact: Kurt Barnhart, MD	215 662 2974

Locations


United States, Pennsylvania
Reproductive Research Unit, U of Penn Medical Center	Not yet recruiting
Philadelphia, Pennsylvania, United States, 19104
Principal Investigator: Kurt Barnhart, MD, MSCE

Sponsors and Collaborators

Biosyn

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Principal Investigator:	Kurt Barnhart, MD	University of Pennsylvania Medical Center

More Information


ClinicalTrials.gov Identifier:	NCT00260767 History of Changes
Other Study ID Numbers:	RRU009
Study First Received:	November 30, 2005
Last Updated:	November 30, 2005

ClinicalTrials.gov processed this record on July 24, 2017

To Top